HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 7

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

, , , ,

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
Now Viewing
EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
EP. 9: Overview of DESTINY-Breast06
EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

  • How would the results of the DESTINY-Breast09 trial impact your clinical practice?
  • What are your thoughts on the other trials mentioned above if they do result in positive results in PFS? How would they be applied to your treatment of different patient subsets?